• Curtana and Catalent Enter Brain Cancer Drug Partnership contractpharma
    July 19, 2021
    Curtana has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana’s CT-179, a drug therapy for the treatment of glioblastoma (GBM), medulloblastoma (MB), and other brain cancers.
PharmaSources Customer Service